Third Rock Ventures V, L.P.'s Form 4 filing
Rapport Therapeutics, Inc. (RAPP) · filed May 28, 2026
- Accession no.
- 0001193125-26-245259
- Filed
- May 28, 2026, 4:15 PM ET
- Trade date
- May 26, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $743.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Third Rock Ventures V, L.P.CIK 0001778071 | 10% Owner |
| Third Rock Ventures VI, L.P.CIK 0001931056 | 10% Owner |
| Third Rock Ventures GP V, LPCIK 0001977498 | 10% Owner |
| Third Rock Ventures GP VI, L.P.CIK 0001977499 | 10% Owner |
| TRV GP VI, LLCCIK 0001990716 | 10% Owner |
| TRV GP V, LLCCIK 0001990717 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 26, 2026 | Common Stock | SSaleDisposed | −18,572 | $40.05F2 | −$743,752.88 | 6,280,525 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).
Referenced by the price of 1 transaction in Table I.